Abstract:Journal of Oncology Pharmacy Practice, Ahead of Print. IntroductionMalignant hematology (MH) patients are susceptible to invasive fungal infections due to prolonged neutropenia and immunosuppressive therapies, which may require voriconazole therapy. Although voriconazole therapeutic drug monitoring (TDM) is common, evidence describing this practice is limited. The primary objective of this study was to describe the current practice of voriconazole TDM in MH patients at the Princess Margaret Cancer Centre (PM).MethodsA retrospective chart review was conducted for MH inpatients initiated on voriconazole at PM between November 1st, 2019 and November 13th, 2020. Data regarding voriconazole doses, levels, dose changes, and adverse effects were collected. The primary endpoint was the proportion of patients with initial voriconazole levels within therapeutic range (1–5 mg/L).ResultsFifty-six patients were included in the study. The most common reason for starting voriconazole was possible invasive fungal infection (44 patients, 78.6%). Fifty-one patients (91.1%) received a loading dose of voriconazole, averaging 386.5 ± 78.5 mg. The average maintenance dose was 242.1 ± 45.7 mg. An average of 2.6 ± 2.9 levels were drawn per patient with an average level of 3.2 ± 2.4 mg/L. Forty-one patients (73.2%) had an initial voriconazole level within therapeutic range and 90 out of 145 total levels (62.1%) were within therapeutic range. There were 52 dose modifications made; 31 (60.8%) doses adjusted, 12 (23.5%) doses held, and 9 (17.6%) doses discontinued. For the 31 dose adjustments, 26 (83.9%) had a level redrawn and 17 (65.4%) of those levels were within therapeutic range. Twenty-three (41.1%) patients developed adverse effects, 8 (34.8%) of which were associated with supratherapeutic levels. Of these 23 patients, 19 (33.9%) experienced transaminitis, 3 (5.4%) experienced both transaminitis and neurotoxicity, and 1 (1.8%) experienced photopsia.ConclusionOverall, 41 (73.2%) patients achieved an initial voriconazole level within therapeutic range. Of these 41 patients, 30 (73.2%) remained within therapeutic range for the duration of their inpatient voriconazole therapy. These findings suggest that the current practice of voriconazole TDM at our institution is yielding largely positive results, but still has room for improvement.

Voriconazole in the treatment of invasive fungal infection in hematologic patients: report of 23 cases

Voriconazole in the Treatment of Invasive Fungal Disease in Patients with Hematologic Malignancies: Report of 12 Cases

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

The Efficacy and Safety of Voriconazole As Antifungal Prophylaxis of Invasive Fungal Infection for Hematology Patients

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients A retrospective observational study

Successful Voriconazole Treatment of Talaromyces Marneffei Infection in an HIV-negative Patient with Osteolytic Lesions.

A Retrospective Study of Efficacy and Safety of Itraconazole for Treatment of Invasive Fungal Infection in Hematologic Diseases

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in the Treatment of Invasive Fungal Infections in Patients Refractory to or Intolerant of First-Line Therapy.

[Clinical Investigation of Reduced-Dose Voriconazole on Primary Prevention in Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation].

[Efficacy of Intravenous Administration of Itraconazole on Fungal Infections in Immunocompromised Patients with Hematological Diseases].

[Efficacy and Safety of Intravenous Itraconazole in Different Antifungal Strategies for Patients Undergoing Intensive Chemotherapy or Hematopoietic Stem Cell Transplantation].

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

Effectiveness and Safety of Isavuconazole Prophylaxis for Invasive Fungal Infections in the Haematologic Setting.

[Itraconazole for Treatment of Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation].

Meta-analysis of Therapeutic Efficacy of Itraconazole Against Invasive Fungal Infection in Hematology Patients

Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Primary Prophylatic Effect of Voriconazole Against Invasive Infection of Pulmonary Aspergillosis During Remission-Induction Chemotherapy for Acute Myeloid Leukemia

Hyperlipidemia Caused by Voriconazole: A Case Report